Somewhere around the third sleepless night after “there’s nothing more we can do,” most families start typing some version of the same search: clinical trials pancreatic cancer stage 4 near me, or ALS experimental drug 2026, or just what do I do now. They land on ClinicalTrials.gov, scroll through 400 listings written in a dialect that seems designed to keep them out, and close the tab feeling worse than when they opened it.

Here’s the thing nobody tells them up front: “clinical trial” is doing the work of three completely different concepts, and almost everyone searching for one is only checking for the first.

There’s the trial that’s already open and recruiting, sitting in a database somewhere. There’s getting early access to a specific drug that isn’t approved yet but might already exist for someone else’s disease. And then there’s the option almost nobody knows exists — having something built, from nothing, for one patient. For one mutation. For your kid, or your father, specifically.

Most families only ever open the first door. Some of them didn’t need to stop there.

The words matter more than you’d think

Quick vocabulary, because using the wrong term with the wrong person wastes days you don’t have.

A clinical trial is a structured study testing a drug, device, or intervention on a group of people, with defined phases. Phase I is mostly about safety and dosing — figuring out how much of the drug a human body can tolerate without falling apart. Benefit is a secondary hope, not the point. Phase II starts looking at whether it actually works. Phase III is the big comparative study that gets a drug approved. If someone tells you “there’s a Phase I trial for that,” don’t hear “there’s a treatment.” Hear “there’s an experiment, and you’d be an early subject in it.”

Expanded access and Right to Try are not the same thing, even though people — and plenty of articles — use the terms interchangeably. Expanded access (still widely called “compassionate use”) is an FDA-authorized pathway: a doctor requests an investigational drug for a named patient, the FDA has to sign off, and it approves the large majority of applications it receives. Right to Try, a 2018 federal law, skips the FDA step entirely — a terminally ill patient can try a drug that’s cleared Phase I without federal permission. In both cases, though, the drug’s manufacturer still has to agree to provide it. That’s the bottleneck neither law removes.

Here’s the difference laid out plainly:

	Clinical Trial	Expanded Access	Right to Try
What it is	Structured study with a set protocol	One-off request for a specific investigational drug	Direct patient/manufacturer request, no FDA role
Who approves it	Trial sponsor + IRB	FDA + manufacturer	Manufacturer only
How fast	Depends on enrollment status	Often weeks, once filed	No FDA delay, but rarely used in practice

Right to Try sounds like the faster option because it cuts out a regulator. In practice, it’s used only a handful of times a year nationally, against thousands of expanded access approvals through the FDA pathway — because the manufacturer’s willingness was always the real gatekeeper, not the FDA.

N-of-1 therapy is the term almost nobody has heard of, and it’s the most interesting thing happening in this space right now. More on that below.

Five minutes with this vocabulary will save you a week of talking past your own doctor.

Get your ammunition before you start searching

Before any database, any matching service, any phone call — you need three things assembled, and most families don’t have them on day one because nobody tells them to ask.

Full medical records. Every prior treatment and how the patient responded to it. And — this is the one that actually determines what you’re eligible for — genomic or molecular testing results. Comprehensive tumor sequencing, a genetic panel, whatever applies to the diagnosis. Trials increasingly recruit by mutation, not by disease name. “Pancreatic cancer” tells a matching algorithm almost nothing. A specific KRAS mutation, or a BRCA status, or a particular fusion gene — that’s a key that opens actual doors.

If this testing hasn’t been done, ask why not, today. It’s often the single biggest hidden delay in this entire process, and it’s fixable faster than almost anything else on this list.

Say this one sentence to your oncologist

Doctors are busy, standard-of-care is the default groove they operate in, and most won’t proactively raise experimental options unless asked — not because they’re hiding anything, but because it’s not the next line item in a normal fifteen-minute appointment.

Say, explicitly: “I want you to actively consider me for clinical trials, including any that aren’t fully open for enrollment yet.”

That second clause matters. Academic medical centers and NCI-designated cancer centers frequently know about trials before they’re visible on public databases — trials still finalizing their protocol, or not yet fully staffed for enrollment, or technically open but not broadly advertised. Telling your doctor you’re interested, out loud, can surface options a database search never will. This is the cheapest, fastest step on this entire list, and it’s the one most families skip because it feels like they’d be insulting their doctor by asking. You won’t be.

Search several places at once, not one after another

Don’t work through this list top to bottom over two weeks. Do it in parallel, over a weekend, and split it across whoever’s helping you.

ClinicalTrials.gov. Comprehensive and free, and also not built for a scared person trying to parse it at midnight. Use it, but don’t expect it to hold your hand.

The NCI’s trial finder. At cancer.gov, backed by the 1-800-4-CANCER line — real people who can talk you through eligibility over the phone.

Disease-specific registries. These exist for most major conditions and are usually better curated than the general databases. The Alzheimer’s Association runs TrialMatch, a continuously updated registry connecting patients with dementia research. Look for the equivalent for your specific disease — these almost always exist and are almost always free.

Institutional matching programs. At NCI-designated cancer centers, these check your case against that center’s entire trial portfolio, not just what one oncologist happens to know. If you’re near one, use it.

AI-assisted matchers. These have gotten genuinely better in the last two years, and it’s worth being honest about that instead of dismissive. Tools like TrialMatchAI, published in Nature in early 2026, go beyond keyword matching — they assess eligibility criterion by criterion and can explain their reasoning, which matters because a black-box “you’re 80% matched” score is close to useless to a family trying to decide where to spend their remaining energy. Commercial services like Massive Bio use AI matching too, sometimes bundled with case management support. Treat these as a strong first pass, not a final answer — always verify anything promising with the trial site directly.

The Undiagnosed Diseases Network. Worth knowing about specifically if your case doesn’t have a clear diagnosis yet, which happens more often than people expect with rare neurodegenerative conditions.

If nothing’s currently open — expanded access and Right to Try

Say you’ve found the right drug, but the trial isn’t recruiting near you, or you don’t meet its criteria. This is where expanded access comes in, and here’s the part that trips people up: you don’t request this yourself. Your physician does, directly with the drug’s manufacturer, and increasingly with updated FDA guidance issued in late 2025 to streamline the process.

Ask your doctor to identify the specific drug and specific manufacturer, not just “something experimental.” A vague request goes nowhere. A named drug with a named sponsor is something your doctor’s office can actually act on.

Right to Try exists as a parallel path if expanded access stalls, but go in with correct expectations, per the table above — it removes the FDA from the decision, not the manufacturer.

The door almost nobody knows about

In 2016, a six-year-old named Mila Makovec was diagnosed with a rare, fatal form of Batten disease. There was no trial for her condition. There was no drug. There wasn’t going to be one — the mutation was so rare it would never justify a pharmaceutical company’s investment.

A neurogeneticist at Boston Children’s named Timothy Yu looked at her specific genetic defect and realized it resembled the splicing problem that an already-approved drug, Spinraza, was designed to correct — just in a completely different gene. His team designed an entirely new antisense oligonucleotide from scratch, built specifically for Mila’s exact mutation, tested it in her own cells, cleared a rat safety study, and had FDA authorization for an N-of-1 trial — all within about a year of first meeting her. They named the drug milasen, after her.

It didn’t cure her. Batten disease had already done damage that couldn’t be reversed, and she passed away a few years later. But it measurably reduced her seizures and, by her family’s account, gave her a better quality of life in the time she had left. And it did something bigger: it proved a custom drug could go from diagnosis to human treatment in about a year, for one person, when nothing else existed.

Her mother, Julia Vitarello, didn’t stop there. She founded Mila’s Miracle Foundation and helped launch the N=1 Collaborative, a nonprofit built specifically to help other families and researchers walk the same path without reinventing it from zero each time. The n-Lorem Foundation, spun out of the biotech company Ionis, now works on exactly this — free, individualized antisense therapies for patients with vanishingly rare mutations, no commercial market required.

I want to be straight with you about the limits here, because this is exactly the point where hope tips over into something crueler if it’s oversold. This approach works for a specific category of problem: a single, identified genetic mutation, in a disease mechanism that responds to splice-modulation or similar gene-silencing approaches. It is not a path that exists for most solid tumors, including stage IV pancreatic cancer. It’s real, it’s growing, and organizations are actively taking on new cases — but it applies to a narrower slice of situations than the emotional pull of Mila’s story might suggest. If your case involves an identified single-gene mutation and standard options are exhausted, it is absolutely worth asking a genetics center or rare disease specialist whether this door is even architecturally possible for your situation. For a lot of families, the honest answer will be no. For some, it will change everything.

Where paying for help actually fits

Concierge medical services and trial-matching brokers exist across a wide price range — some outfits charge a few hundred dollars a year, others operate more like a private bank for healthcare, serving thousands of well-off clients with a dedicated case team.

Here’s what you’re actually buying when you pay: time, and relationships. A good broker knows which oncologist at which center to call directly instead of going through a general intake line. They chase paperwork you don’t have the bandwidth to chase. They’ve done this fifty times and you’re doing it once, in the worst week of your life.

What you are usually not buying is access to some hidden database the rest of us can’t see. The underlying trial data is largely public. The value is in navigation, not in secret information.

My honest read: pay for this if you have the money and no time or energy left to do the legwork yourself, or if the case is genuinely complex — multiple prior treatments, an ambiguous diagnosis, international options on the table. Don’t pay for it if a phone call to an NCI-designated cancer center’s trial-matching office and a few hours on the resources above would get you 90% of the way there for free. For most families, it will.

How to spot the ones exploiting you instead of helping you

The FDA has spent years sending warning letters to clinics selling unapproved stem cell and “regenerative medicine” treatments to desperate patients — treatments the agency says have caused blindness, tumor growth, and serious infections, with essentially zero evidence they help the conditions they’re marketed for, including Alzheimer’s, ALS, and heart disease.

Three red flags to check before you trust a clinic or “specialist” with your money or your time:

• You’re asked to pay significant cash upfront for the treatment itself — not travel or logistics around a registered trial, but the investigational product. Real trials almost never charge for this.
• The clinic isn’t listed on ClinicalTrials.gov and can’t name an IRB (institutional review board) that approved the protocol.
• The same clinic claims to treat an unusually wide range of unrelated conditions — arthritis and autism and heart disease and Parkinson’s, all with the same injection. That’s not innovation. That’s a business model built on hope rather than evidence.

What to actually expect

I’d rather tell you this straight than let you find out later. Most patients who enroll in a Phase I trial do not experience dramatic remission — that was never really the design goal of Phase I in the first place. Expanded access requests, when they go through, are aimed at extending life or improving quality of life, not reliably reversing a terminal diagnosis. N-of-1 therapy, even in the best-documented case, didn’t save the child it was built for.

None of that means the effort is wasted. It means “success” here often looks like more time, better symptom control, or contributing data that helps the next patient with the same mutation — not a cure pulled from a filing cabinet nobody else thought to open. Go in eyes open, and the process will feel less like gambling and more like what it actually is: methodical, occasionally frustrating, sometimes genuinely fruitful work.

The order to actually do this in

1. Get full records and, if not already done, comprehensive genomic/molecular testing — today, not next week.
2. Tell your treating physician directly you want to be considered for trials, including ones not yet fully open.
3. Search ClinicalTrials.gov, the NCI trial finder, your disease’s dedicated registry, and an AI-assisted matcher — in parallel, over one weekend.
4. If a specific drug looks right but isn’t accessible through a trial, have your doctor initiate an expanded access request with the manufacturer by name.
5. If your case involves an identified single-gene mutation and nothing above works, ask a genetics or rare disease center whether an n-of-1 approach is biologically plausible.
6. Consider a paid broker only once you know what you’re missing — time, connections, or bandwidth — not before.
7. Verify any clinic that isn’t a major academic center against ClinicalTrials.gov and IRB registration before sending anyone money.

There’s no version of this where the search is easy. But it’s not random, either — there’s a real order of operations here, and most people never hear it laid out before they’ve already burned a week going in circles.